Morgans Under the Microscope

Dr Asher Freilich, CEO and founder of the online scripts business InstantScripts explains how concept evolved into a rapidly growing operation with big plans for the future.

Dr James Fielding founder and CEO of Audeara provides an update on the company’s progress.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU#Healthcare

Rob Wong CEO of Control Bionics provides an update on the company’s progress.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU#Healthcare

Scott Power, Senior Analyst at Morgans speaks to the Morgans network. He updates on stocks in the Healthcare sector such as: Nanosonics (NAN), Resmed (RMD), Mach 7 (M7T), Impedimed (IPD), Audeara (AUA), Antisense Therapeutics (ANP), Neuren Pharmaceuticals (NEU).Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU

Ralph Highnam CEO and founder of Volpara Health (VHT.ASX) explains the significance of the technology and how its successfully being deployed across many breast clinics.

Peter Rowland MD of Micro-X explains the significance of the next generation X-ray technology for global health and security markets.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU#X-ray #Security #Healthcare

Morgans healthcare analyst Iain Wilkie talks to Dr James Fielding, CEO of new IPO entrant Audeara (ASX:AUA) on what the company does and where its products fit within the audiology space.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU#Innovation #Healthcare

Rob Wong Chief Executive Officer of Control Bionics, speaks with Scott Power from the Morgans Healthcare team, providing an update on the significant progress the company is making.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU#Innovation #Healthcare

Morgans analyst Iain Wilkie speaks with Chief Executive Officer and Managing Director of ResApp (ASX:RAP), Tony Keating. Tony provides an update on a number of recent news events.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU

Morgans Senior Analysis, Dr. Derek Jellinek, provides an update on the healthcare universe, including key upcoming catalysts.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU#Healthcare #Stocks #ReportingSeason

Morgans Healthcare Analyst Iain Wilkie talks to Pippa Leary, Chief Executive Officer of Swift Media (ASX:SW1) for a high-level overview of the business, catalysts, and its shift into the large aged care sector.

Scott Power from the Morgans Healthcare team speaks with Peter Rowland, CEO from Micro-X (ASX: MX1) where he explains the technology, its application, and upcoming catalysts for 2021.

Healthcare analysts Iain Wilkie and Scott Power wrap up the week with a review and call out on stocks in the IVF sector such as: Virtus Health (VRT) and Monash IVF Group (MVF). Some other stocks mentioned are ImexHS (IME), Swift Media (SW1), and Impedimed (IPD).

Senior Analyst Scott Power from the Morgans Healthcare team speaks with Jon Pilcher, Chief Executive Officer of Neuren Pharmaceuticals (ASX:NEU). Jon explains a number of key catalysts which are expected in 2021.

Morgans analyst Iain Wilkie discusses the healthcare team's initiation of coverage for Antisense Therapeutics (ASX:ANP) and highlights Neuren Pharmaceuticals (ASX:NEU) as a stock with key catalysts ahead.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/morgans.australiaOn Twitter: twitter.com/morgansAU

Scott Power from the Morgans Healthcare team runs through a number of themes for 2021 together with some upcoming catalysts. Stocks mentioned include Pro Medicus (PME), Nanosonics (NAN), EBOS Group (EBO), Micro-X (MX1), Impedimed (IPD) Volpara Health Technologies (VHT), and ResMed (RMD).Check out more from Morgans:Visit the Morgans website: https://www.morgans.com.auCheck out our blog: https://www.morgans.com.au/BlogOn Facebook: https://www.facebook.com/MorgansAUOn Instagram: https://www.instagram.com/morgans.australiaOn Twitter: https://twitter.com/morgansAU#Healthcare #Technology #Morgans

Morgans Analyst Iain Wilkie chats with Claude Solitario, Managing Director of ASX listed mental health technology company Medibio (ASX:MEB). The two chat about an update on a recent partnership as well as a number of upcoming catalysts.

The Morgans Healthcare provides an update on the following companies Promedicus (PME), Nanosonics (NAN), Resmed (RMD), Volpara (VHT), Virtus (VRT), Impedimed (IPD), and Micro-X (MX1)

The Morgans Health team provides an update on the aged care sector and key catalysts achieved (stocks mentioned Micro-X, Impedimed, Virtus, Volpara, Mach 7 and Paradigm)

Morgans analyst Iain Wilkie chats to Dr Sean Hall who is the CEO and MD of drug development company Medlab Clinical (ASX:MDC) on some recent news and upcoming catalysts.

Morgans Senior Analyst Scott Power recaps the healthcare picks for and what to look out for across the current active opportunities.Some of the companies Scott talks about are: Mach7 Technologies (ASX:M7T), Impedimed (ASX:IPD), Micro-X(ASX:MX1), and Neuron Pharmaceuticals (ASX:NEU).

Morgans Analyst Iain Wilkie talks with ResApp (ASX:RAP) CEO, Tony Keating, on a number of recent partnership agreements.

Morgans Senior Analyst, Dr. Derek Jellinek, provides a comprehensive update on the Covid-19 Vaccine. Additionally, Derek breaks down the key stakeholders within the race, and how they are currently positioned.

Neuren Pharmaceuticals’ (ASX:NEU) Chief Executive Officer, Jon Pilcher, sits down with Senior Analyst Scott Power. In this piece, Jon outlines a number of upcoming value drivers for the company.

Morgans Senior Analyst Scott Power notes three upcoming catalysts for Volpara (ASX:VHT) which are likely to move the share price higher.

Morgans Analyst Iain Wilkie recaps the healthcare teams picks for 2020 and what to look out for across the current active opportunities.

Michelle Gallaher, CEO of Opyl Ltd (ASX:OPL) provides an update to the network on what the company does, operational update, a number of new clients, and a potential opportunity ahead.

Morgans analyst Iain Wilkie sat down with Leo Lee, CEO of ASX listed regenerative medicine player Regeneus (ASX:RGS). The two speak on its recent partnership deal for osteoarthritis in Japan and what it means for the company.

Morgans Senior Healthcare Analyst Scott Power highlights four key buys with the Healthcare sector – ResMed (ASX:RMD), Virtus Health (ASX:VRT), EBOS (ASX:EBO) and Nanosonics (ASX:NAN).

Morgans analyst Iain Wilkie runs through a number of healthcare stocks reporting quarterly statements over the week as well as a broader market wrap.

Morgans Analyst Iain Wilkie provides an update on the healthcare market and discusses a some significant swings in a number of micro-cap stocks and highlights two stocks worth watching for the upcoming cashflow reporting season this month.

Morgans Healthcare Analyst Scott Power provides an update on Mach 7 (M7T) following their successful capital raising.

Cochlear (COH) gains FDA’s blessing on multiple products, but nothing appears game-changing.

Bob Proulx CEO of Imagion Biosystems (IBX) provides an update on the company’s progress after it announced plans to start human studies using its MagSense technology.

Morgans Analyst Iain Wilkie talks to CEO of ASX listed regenerative medicine and stem-cell player Regeneus (ASX:RGS) on what the company does and a number of potential catalysts which lie ahead.

ResApp Health (RAP) CEO Tony Keating provides an update on the progression of commercialisation of its diagnostic into the telehealth setting, an update on the SleepCheck product, and outlines a number of key drivers ahead.

Healthcare analyst Iain Wilkie gives another market update and runs through a number of small cap healthcare announcements over the week.

Scott Power provides comments on CSL, Sonic, Promedicus, Nanosonics and Volpara.

Jon Pilcher CEO of Neuren Pharmaceuticals provides an update on the clinical trials the company is undertaking.

Healthcare analyst Iain Wilkie runs through a number of healthcare announcements over the week and recaps a few trading ideas which have performed strongly over the last few weeks.

Scott Power part of the Morgans Healthcare team provides an update on Volpara after successfully completing its capital raising.

Morgans Senior Analyst Derek Jellinek discusses RMD 3Q results and strong resilience shown across the core business and incremental gains from COVID-19 induced demand for ventilators.

Healthcare analyst Iain Wilkie runs through some market news, a number of updates for stocks under coverage, and some comments on the relaxation of a number of elective medical procedures announced over the week.

Morgans Senior Analyst Scott Power updates the network with information on 3 companies: Volpara (ASX:VHT), Impedimed (ASX:IPD) and Micro-X (ASX:MX1).

Morgans Research Analyst Iain Wilkie talks with Michelle Gallaher, CEO of Opyl Limited (#ASX : $OPL). Michelle gives a recap on a number of products coming to market, a new partner to expand its reach, and what potential investors can look out for.

Morgans Research Analyst Iain Wilkie talks with Mark Diamond, Managing Director of Antisense Therapeutics (ASX:ANP). Mark shares a recap on what the company does, and what potential investors can look out for.

Morgans Senior Analyst Scott Power, close out on the week that was 3/04/2020. He shares an update on the Healthcare sector and run through a couple of stocks to look out for.

Morgans Analyst Iain Wilkie and Senior Analyst Scott Power, close out on the week that was 20/03/2020. They run through another tough week on the market, and provide an update on some of their stocks under coverage.

Morgans Analyst Iain Wilkie and Senior Analyst Scott Power, close out on the week that was 13/03/2020. They run through a number of announcements from over the week and share a market wrap on what was one of the sharpest weekly declines in recent years.

Dr Chris Hart (CEO and founder) provides an update on Oventus’ progress.